KNACK PHARMA
LIVE

Serial Number

97425869

Owner

Knack Pharmaceuticals, Inc.

Attorney

Tomas M. Casalins

Filing Date

May 24, 2022

Add to watchlist:

No watchlists yet
View on USPTO

KNACK PHARMA Trademark

Serial Number: 97425869

KNACK PHARMA is a trademark filed by Knack Pharmaceuticals, Inc. on May 24, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Knack Pharmaceuticals, Inc.

885 Third Avenue, 17th Floor
New York, NY 10022

Entity Type: 03

Trademark Details

Filing Date

May 24, 2022

Registration Date

Not Registered

Published for Opposition

April 25, 2023

Goods & Services

Advertising planning; Advertising services, public relations and marketing services, namely, promoting and marketing the goods and services of others through all public communication means; Business management; Business operation, business administration and office functions

Pharmaceutical preparations for the treatment and prevention of psychological disorders; Pharmaceutical preparations for the treatment and prevention of epilepsy disorders; Pharmaceutical preparations for the treatment and prevention of diabetes and diabetic neuropathy; Pharmaceutical preparations for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations for the treatment and prevention of neurodegenerative diseases and disorders; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of pain and neuropathic pain; Pharmaceutical preparations for the treatment and prevention of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of respiratory system diseases and disorders; Pharmaceutical preparations for the treatment and prevention of skin diseases, allergies and rheumatic disorders; Pharmaceutical preparations for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Pharmaceutical preparations for the treatment and prevention of Alzheimer's disease; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of ophthalmic related disorders and diseases; Pharmaceutical preparations for the treatment and prevention of musculoskeletal related diseases and disorders; Pharmaceutical preparations for the treatment and prevention of hormone disorders and deficiencies; Pharmaceutical preparations for the treatment and prevention of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the treatment and prevention of metabolic, endocrine and kidney related diseases and disorders; Pharmaceutical preparations for the treatment and prevention of nausea and vomiting; Pharmaceutical preparations for the treatment and prevention of AIDS-related disorders and diseases; Pharmaceutical preparations for the treatment and prevention of viral and bacterial infections; Pharmaceutical preparations for the treatment and prevention of depression; Pharmaceutical preparations for the treatment of exposure to toxic agents; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the support and promotion of bone strength and health; Pharmaceutical preparations for use as injectable anesthetics; Pharmaceutical preparations for use as contraceptives; Pharmaceutical preparations for fertility enhancement purposes; Pharmaceutical preparations for use in hormone replacement therapy; Pharmaceutical preparations for inducing labor and facilitating nursing; Pharmaceutical preparations, namely, injectable contraceptives

Filing History

REVIEW OF CORRESPONDENCE COMPLETE
May 20, 2026 CORV
TEAS POST PUBLICATION AMENDMENT RECEIVED
May 19, 2026 EPPA
TEAS PETITION TO AMEND BASIS RECEIVED
May 18, 2026 TPAD
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 9, 2026 EXRA
SOU EXTENSION 5 GRANTED
May 8, 2026 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 8, 2026 AITU
SOU TEAS EXTENSION RECEIVED
Dec 10, 2025 EEXT
SOU EXTENSION 5 FILED
Dec 9, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 21, 2025 EXRA
SOU EXTENSION 4 GRANTED
Jun 20, 2025 EX4G
SOU EXTENSION 4 FILED
Jun 20, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 20, 2025 EEXT
SOU EXTENSION 3 GRANTED
Dec 14, 2024 EX3G
SOU EXTENSION 3 FILED
Dec 14, 2024 EXT3
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 13, 2024 EXRA
SOU TEAS EXTENSION RECEIVED
Dec 13, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 18, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jun 18, 2024 EX2G
SOU EXTENSION 2 FILED
Jun 18, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 18, 2024 EEXT
ASSIGNED TO EXAMINER
May 1, 2024 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 21, 2023 EXRA
SOU EXTENSION 1 GRANTED
Dec 19, 2023 EX1G
SOU EXTENSION 1 FILED
Dec 19, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 19, 2023 EEXT
ASSIGNED TO EXAMINER
Nov 13, 2023 DOCK
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 20, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 25, 2023 NPUB
PUBLISHED FOR OPPOSITION
Apr 25, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 5, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 20, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 16, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 16, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 16, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 16, 2023 CNEA
ASSIGNED TO EXAMINER
Mar 12, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 31, 2022 NWOS
NEW APPLICATION ENTERED
May 27, 2022 NWAP